- Home
- HCKT vs NGNE Comparison
HCKT vs NGNE Comparison
Compare HCKT & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCKT
- NGNE
- Stock Information
- Founded
- HCKT 1991
- NGNE 2003
- Country
- HCKT United States
- NGNE United States
- Employees
- HCKT N/A
- NGNE N/A
- Industry
- HCKT Professional Services
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- HCKT Consumer Discretionary
- NGNE Health Care
- Exchange
- HCKT Nasdaq
- NGNE Nasdaq
- Market Cap
- HCKT 492.7M
- NGNE 426.6M
- IPO Year
- HCKT 1998
- NGNE N/A
- Fundamental
- Price
- HCKT $18.65
- NGNE $20.56
- Analyst Decision
- HCKT Buy
- NGNE Strong Buy
- Analyst Count
- HCKT 1
- NGNE 6
- Target Price
- HCKT $27.00
- NGNE $38.50
- AVG Volume (30 Days)
- HCKT 354.0K
- NGNE 253.0K
- Earning Date
- HCKT 11-04-2025
- NGNE 11-13-2025
- Dividend Yield
- HCKT 2.61%
- NGNE N/A
- EPS Growth
- HCKT N/A
- NGNE N/A
- EPS
- HCKT 0.38
- NGNE N/A
- Revenue
- HCKT $303,482,000.00
- NGNE N/A
- Revenue This Year
- HCKT $2.33
- NGNE N/A
- Revenue Next Year
- HCKT $4.84
- NGNE N/A
- P/E Ratio
- HCKT $47.99
- NGNE N/A
- Revenue Growth
- HCKT 0.91
- NGNE N/A
- 52 Week Low
- HCKT $17.53
- NGNE $6.88
- 52 Week High
- HCKT $34.02
- NGNE $37.27
- Technical
- Relative Strength Index (RSI)
- HCKT 52.85
- NGNE 35.57
- Support Level
- HCKT $17.60
- NGNE $19.68
- Resistance Level
- HCKT $18.46
- NGNE $22.42
- Average True Range (ATR)
- HCKT 0.39
- NGNE 2.46
- MACD
- HCKT 0.06
- NGNE -1.00
- Stochastic Oscillator
- HCKT 64.55
- NGNE 6.24
About HCKT Hackett Group Inc (The).
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.